NEW YORK (GenomeWeb) – Qiagen is taking aim at the high-throughput, high-volume molecular diagnostics market through its recently announced partnership and merger agreement with molecular diagnostics developer NeuMoDx.

The deal calls for Qiagen to initially distribute the NeuMoDx N288 and NeuMoDx N96 fully integrated molecular testing platforms in Europe and other ex-US markets, while Ann Arbor, Michigan-based NeuMoDx will continue to market its systems and tests in its home country.